These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 21122380)

  • 61. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
    Sun JM; Won YW; Kim ST; Kim JH; Choi YL; Lee J; Park YH; Ahn JS; Park K; Ahn MJ
    J Cancer Res Clin Oncol; 2011 Apr; 137(4):687-94. PubMed ID: 20552223
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
    Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
    PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
    [TBL] [Abstract][Full Text] [Related]  

  • 63. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
    Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O
    Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
    Takeda M; Okamoto I; Nakagawa K
    J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
    Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
    Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
    Locatelli-Sanchez M; Couraud S; Arpin D; Riou R; Bringuier PP; Souquet PJ
    Lung; 2013 Oct; 191(5):491-9. PubMed ID: 23749122
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
    Ulivi P; Delmonte A; Chiadini E; Calistri D; Papi M; Mariotti M; Verlicchi A; Ragazzini A; Capelli L; Gamboni A; Puccetti M; Dubini A; Burgio MA; Casanova C; Crinò L; Amadori D; Dazzi C
    Int J Mol Sci; 2014 Dec; 16(1):747-57. PubMed ID: 25561229
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
    Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF
    PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China.
    Li M; Zhang Q; Liu L; Liu Z; Zhou L; Wang Z; Yue S; Xiong H; Feng L; Lu S
    Neoplasma; 2011; 58(1):74-81. PubMed ID: 21067269
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Mutation status of epidermal growth factor receptor and KRAS gene in non-small cell lung cancers at Xuanwei regions of Yunnan Province].
    Yang CS; Pan XY; Feng Q; Wang YY; Xu WM; Jiang T; Wang L; Yang JL; Wang L
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):226-30. PubMed ID: 27033384
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer].
    Li Z; Zhang LJ; Wang WP; Guo K; Shao JY; Rong TH
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):666-70. PubMed ID: 22340046
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
    Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
    Yeo WL; Riely GJ; Yeap BY; Lau MW; Warner JL; Bodio K; Huberman MS; Kris MG; Tenen DG; Pao W; Kobayashi S; Costa DB
    J Thorac Oncol; 2010 Jul; 5(7):1048-53. PubMed ID: 20512075
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
    BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.